Vomiting
Conditions
Keywords
nausea, vomiting, Carboplatin, cancer, delayed emesis following treatment with carboplatin
Brief summary
Delayed emesis following administration of carboplatin-based chemotherapy despite prophylaxis with standard antiemetic prophylaxis (5-HT3 and corticosteroid) remains a clinically significant and distressing problem for patients with cancer. The incidence of delayed emesis appears to be higher in women compared to men.
Detailed description
All patients will be given the Functional Living Index- Emesis (FLIE), a standardized questionnaire. This is a self-administered questionnaire to assess the impact of nausea and vomiting on the patient's functional living, including physical activities, social and emotional function, and ability to enjoy food and drink. Patients will complete the questionnaire during the 5 days following carboplatin administration (at 24 hours, 48 hours, 72 hours and 96 hours) during their first and third cycles of chemotherapy. The questionnaire should take approximately 10 minutes or less to complete. Patients will also be interviewed by a trained CRA or research nurse over the telephone 24-48 hours following carboplatin administration in order to assess the severity of the delayed nausea and vomiting.
Interventions
BEHAVIORALFunctional Living Index - Emesis
Sponsors
Merck Sharp & Dohme LLC
Washington University School of Medicine
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have newly diagnosed, histologically or cytologically proven cancer, and be scheduled to receive chemotherapy with carboplatin at AUC 5 or above. * Patients should receive standard antiemetic prophylaxis prior to carboplatin administration, defined as 5-HT3 antagonist and dexamethasone. We will include only patients whose standard care includes treatment with a carboplatin-containing regimen and who are not being treated with aprepitant (Emend®). * Age \>= 18. * After being informed of the treatment involved, patients must give written consent. * Entry to this study is open to both men and women and to all racial and ethnic subgroups.
Exclusion criteria
* No prior cytotoxic chemotherapy within the last 5 years. * Should not be pregnant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Characterize the incidence of delayed emesis following administration of carboplatin-containing chemotherapy regimens | After 1st cycle of chemotherapy | Despite appropriate administration of standard 5-HT3 receptor antagonist antiemetic prophylaxis after the first cycle of chemotherapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Characterize the incidence of delayed emesis following administration of carboplatin-containing chemotherapy regimens | After 3rd cycle of chemotherapy | Despite appropriate administration of standard antiemetic prophylaxis after the third cycle of chemotherapy |
| Characterize the differences in incidence of delayed nausea and vomiting among male and female patients receiving carboplatin. | Through the end of 3 cycles of therapy | — |
| Assess the need for breakthrough nausea and vomiting control in patients following administration of carboplatin-containing chemotherapy regimens | Through the end of 3 cycles of therapy | Despite appropriate administration of standard antiemetic prophylaxis. |
Countries
United States
Outcome results
None listed